Tharos

EIS ELIGIBLE
EQUITY

A patent-rich equine health company focused on optimizing digestion, gut health and the microbiome.

RAISED

Maturity

Market readiness

Sector

Veterinary Health

Market

Equine Health

Goal

£950,000

You can indicate your investment interest in this opportunity without any commitment.

Lead investor

Julie Newman

How the company differentiates themselves

HIGHLIGHTS

  • Racehorses of a well-known flat racing yard fed EquiNectar® demonstrated an increase in performance by 2x winnings and 4x prize money over a 3 year period.
  • EquiNectar® reduces acetate levels in horses. Acetate has been associated with insulin resistance and metabolic syndrome in horses.
  • EquiNectar®will deliver short-term revenues until 2020 in the supplement market, supporting the R&D for our veterinary medicine products, so reducing the need for further dilutive capital.
  • Clinical trials have also identified key biomarkers for laminitis which should lead to diagnostic and therapeutic products by 2019.
  • Directors of Anglo Scientific, the founders of Tharos, have previously founded and sold a gut related business to Nestle Foods for an undisclosed sum.
Wall Street Journal link

What our experts say  

THIS PROJECT HAS BEEN REVIEWED BY THE BIOEXPERT NETWORK OF 500+ PHD LEVEL SCIENTISTS, PHYSICIANS, IP LAWYERS, CONSULTANTS AND INVESTMENT PROFESSIONALS. THEY HAVE RATED THIS PROJECT BASED ON VARIOUS PARAMETERS, INCLUDING: THE SCIENTIFIC VALIDITY, TEAM EXPERTISE, ROUTE TO MARKET, VALUATION AND INVESTABILITY.

The final ratings  

THESE ARE THE AVERAGE SCORES, TAKEN FROM A VARIETY OF REVIEWS PERFORMED BY THE BIOEXPERT NETWORK AND OUR INTERNAL ANALYTICAL TEAM.

Team

WHAT'S THIS?
THE PROFESSIONAL EXPERTISE OF THE TEAM AND OVERALL STRUCTURE OF THE COMPANY.

Science

WHAT'S THIS?
THE CREDIBILITY OF THE SCIENTIFIC RESEARCH AND DEVELOPMENT, THE STATUS OF THE PATENT AND THE ACCURACY OF THE INFORMATION PRESENTED.

Innovation

WHAT'S THIS?
THE NOVEL MERIT OF THE PROJECT AND COMPARISON OF THE COMPANY TO COMPETITORS.

Business

WHAT'S THIS?
THE MATURITY OF THE COMPANY, AND APPROPRIACY OF THE BUSINESS MODEL, PLAN AND ROUTE TO MARKET.

Finances

WHAT'S THIS?
THE PRESENTATION OF FINANCIAL INFORMATION, INCLUDING PRE-MONEY VALUATION, BALANCE SHEET, FORECAST, EXPECTED ROI, EXIT AND ROI JUSTIFICATION.

Approved by the Bioexpert Network

The BioExpert Network is an independent and exclusive network of industry experts in the sectors of life science and investment. Only proposals which receive the most positive responses, in terms of novel concepts, scientific validity and financial accuracy successfully progress to funding campaign stage on the Capital Cell online platform.

Purpose of the project

 

FROM PROBLEM TO SOLUTION

THE PROJECT

TharosTM is focused on restoring health gut function in Equines. Malfermentation in the gut caused by an unbalanced microbiome leads to poor condition and performance, and in some case colic and laminitis.

Studies have shown that key enzymes can help maintain and preserve normal equine body function, optimize the microbiome in the gut, and prevent malfermentation. These findings have led to the development of EquiNectar®, a proprietary dietary supplement. Tharos™ anticipates launching selectively and strategically to the UK market in Q4 2017, followed by a launch to the wider UK market in Q2/3 2018. Tharos™ is developing additional products for equine health, initially focused on three conditions that are important causes of equine mortality and morbidity: laminitis, metabolic syndrome and colic.

THE PROBLEM

Modern feeds do not provide an optimum diet for the horse. Digestive upsets are common because the critical balance of microflora in the horse’s gut, the microbiome is easily perturbed. Perturbations of the microbiome lead to malfermentation, a leaky gut, the formation of toxic substances and the release of damaging bacterial endotoxins into the horse’s circulation.

Horses often develop a cycle of illness beginning with diarrhoea or constipation, and progressing to colic (intestinal disease) and laminitis (hoof disease). Colic and laminitis are both important causes of equine mortality and morbidity. These conditions currently have no known cure, and represent a pressing unmet need in veterinary medicine.

THE SOLUTION

Tharos has developed EquiNectar®, an exzyme-rich malt extract that has been scientifically proven to address malfermentation and pertubations of the microbiome, and to reduce endotoxin and acetate levels. High acetate levels are correlated with insulin resistance and related problems in the horse. There have been no instances of toxicity.

  • EquiNectar® restores and maintains the horse’s microbiome to ensure a healthy gut. The microbiome has been shown to decrease the species known to contribute to toxicity (eg Clostridia, Streptococci) and increase those associated with the healthy gut (Bacterioides). As a result, race horses which commonly alternate between states of constipation and diarrhoea when fed a high-concentrate diet have been found to revert to a normal intestinal function, similar to that found in free-grazing animals

 

  • EquiNectar® improves performance and condition by assisting in the digestion of carbohydrates, through a process which leads to more efficient conversion of feed to energy. Efficient carbohydrate digestion is key to equine health.
  • Preliminary data indicate that EquiNectar®, through similar physiological mechanisms, may also help prevent and treat laminitis, an inflammatory condition of the hoof and its vascular supply which can disable a horse. Additional data is being accumulated.
  • Tharos is also exploring the feasibility of introducing a diagnostic for laminitis based on novel chemical biomarkers to the market by 2020. The link to these biomarkers is patent pending.

Join to see more information

To download the Investment Opportunity Sheet, join now.
It’s free, quick and easy.

Contact the Company

CONTACT THE COMPANY

Leave a Reply